![Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits – JCAD | The Journal of Clinical and Aesthetic Dermatology Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/JCADJune2019GoldenbergTable1.gif)
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits – JCAD | The Journal of Clinical and Aesthetic Dermatology
![Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b843afb8-6390-4599-a869-52d0e3f1e194/gr1.jpg)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet
![PDF] Clinical Trial Development of biologics for the Treatment of Psoriasis Developers are eyeing new therapeutic targets for biologic treatments for psoriasis | Semantic Scholar PDF] Clinical Trial Development of biologics for the Treatment of Psoriasis Developers are eyeing new therapeutic targets for biologic treatments for psoriasis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ffeeb75304a8b3fc8ea12a0628f68df105c3155e/2-Table1-1.png)
PDF] Clinical Trial Development of biologics for the Treatment of Psoriasis Developers are eyeing new therapeutic targets for biologic treatments for psoriasis | Semantic Scholar
![Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials - The Lancet Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2100904528/2079768644/gr1.gif)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials - The Lancet
![Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials - Journal of the American Academy of Dermatology Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dcf78377-dd8a-4a53-b4a6-0c34b86e294a/gr1.jpg)